Given the patient’s rapid PSA elevation following discontinuation of abiraterone after a month of goserelin acetate plus abiraterone, incorporating abiraterone in addition to ADT could be beneficial for patients with PDA. Here, KLK3 is linked to Patent ductus arteriosus.